Daniela Begolo
Managing Director @ EQT Life Sciences
Daniela Begolo is a Series B investor at EQT Life Sciences focused on Medical and Therapeutics. Daniela Begolo is the Board Member of Mosanna Therapeutics and Managing Director of EQT Life Sciences. She attended Heidelberg University.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 67%
Last updated:
For AI agents: llms.txt
Industries Daniela Begolo invests in
Stages Daniela Begolo invests in
Countries Daniela Begolo invests in
Investment Focus
Industry
- Medical 2 (67%)
- Therapeutics 2 (67%)
- Biotechnology 2 (67%)
- Health Care 1 (33%)
- Life Science 1 (33%)
Stage
- Series B 2 (67%)
- Series A 1 (33%)
Country
- Spain 1 (33%)
- Switzerland 1 (33%)
- United States 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Kinaset Therapeutics
|
Kinaset Therapeutics is a therapeutics company that focuses on the advancement of novel drugs in areas of unmet medical needs. The company was founded in 2020 and is headquartered in Medfield, Massachusetts. | $103M / Series B / Jan 10, 2026 | |
Splice Bio
|
Splice Bio is a gene therapy company based on technology developed in the Muir Lab at Princeton University. The company is developing novel gene therapies based on its proprietary intein platform technology to treat patients that suffer from incurable genetic diseases. The company’s platform has the potential to address two existing limitations ofadeno-associated viruses (AAVs), both by increasing the size of the cargo gene that can be delivered and by expanding the range of tissues that can be targeted. | $135M / Series B / Jun 11, 2025 | |
Mosanna Therapeutics
|
Mosanna is a Biotech company based in Basel with a commitment to improving patient outcomes and quality of life in high unmet need diseases, applying a precision medicine approach. | $80M / Series A / Jun 09, 2025 |
Co-Investors
About EQT Life Sciences
EQT life science develops innovative medicines, devices, and tools to address the single important thing that matters to the preservation of health. The organization believes that such opportunities add value to all stakeholders.
EQT Life Sciences Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Christoph Broja
Partner
|
|||
Fouad Azzam
General Partner
|
|||
Joachim Rothe
General Partner
|
|||
|
Daniela Begolo
Managing Director
|
|||
|
Ellen Cordo
Chief Finance
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Daniela Begolo invest in?
Daniela Begolo invests primarily in Medical, Therapeutics and Biotechnology startups, most often at Series B and Series A stage. Most of the 3 investments tracked by Shizune back companies in Spain. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Daniela Begolo last invest?
The most recent investment recorded for Daniela Begolo closed in Jan 2026. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
